Aliases & Classifications for Ocular Hypotension

MalaCards integrated aliases for Ocular Hypotension:

Name: Ocular Hypotension 12 44 15 73
Hypotony of Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:790
ICD10 33 H44.4 H44.40
ICD9CM 35 360.3 360.30
MeSH 44 D015814
SNOMED-CT 68 19721008 23670006
UMLS 73 C0028841

Summaries for Ocular Hypotension

MalaCards based summary : Ocular Hypotension, also known as hypotony of eye, is related to primary eye hypotony and ocular hypertension, and has symptoms including eye manifestations An important gene associated with Ocular Hypotension is HTR2B (5-Hydroxytryptamine Receptor 2B), and among its related pathways/superpathways are Signaling by GPCR and DAG and IP3 signaling. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and heart, and related phenotype is cardiovascular system.

Related Diseases for Ocular Hypotension

Graphical network of the top 20 diseases related to Ocular Hypotension:



Diseases related to Ocular Hypotension

Symptoms & Phenotypes for Ocular Hypotension

UMLS symptoms related to Ocular Hypotension:


eye manifestations

MGI Mouse Phenotypes related to Ocular Hypotension:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.02 ADRB1 ADRB2 HTR2B PDE4A PDE4B

Drugs & Therapeutics for Ocular Hypotension

Drugs for Ocular Hypotension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
3
Carteolol Approved Phase 4 51781-06-7 2583
4
Timolol Approved Phase 4,Phase 2 26839-75-8 33624 5478
5
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
6
Dorzolamide Approved Phase 4,Phase 2 120279-96-1 5284549 3154
7
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
8 Adrenergic Agents Phase 4,Phase 2,Not Applicable
9 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Not Applicable
10 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
12 Autonomic Agents Phase 4,Phase 3
13 Anti-Inflammatory Agents Phase 4,Phase 3
14 HIV Protease Inhibitors Phase 4,Phase 3
15 Antiemetics Phase 4,Phase 3
16 Gastrointestinal Agents Phase 4,Phase 3
17 glucocorticoids Phase 4,Phase 3
18 Hormone Antagonists Phase 4,Phase 3
19
protease inhibitors Phase 4,Phase 3
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
21 Hormones Phase 4,Phase 3
22 BB 1101 Phase 4,Phase 3
23 Antineoplastic Agents, Hormonal Phase 4,Phase 3
24 Antihypertensive Agents Phase 4,Phase 2,Not Applicable
25 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
26 Adrenergic beta-Antagonists Phase 4,Phase 2
27 Ophthalmic Solutions Phase 4,Phase 1,Phase 2
28 Sympatholytics Phase 4
29 Adrenergic Antagonists Phase 4,Phase 2
30 Natriuretic Agents Phase 4
31 diuretics Phase 4
32 Anticonvulsants Phase 4
33 Carbonic Anhydrase Inhibitors Phase 4,Phase 2
34
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
35
Fluorouracil Approved Phase 3 51-21-8 3385
36
Colchicine Approved Phase 3 64-86-8 6167 2833
37
Dalteparin Approved Phase 3 9005-49-6
38
Ranibizumab Approved Phase 3,Not Applicable 347396-82-1 459903
39 Antirheumatic Agents Phase 3
40 Anticoagulants Phase 3
41 Calcium, Dietary Phase 3
42 Heparin, Low-Molecular-Weight Phase 3
43 calcium heparin Phase 3
44 Fibrinolytic Agents Phase 3
45 Antimitotic Agents Phase 3
46 Angiogenesis Inhibitors Phase 3,Not Applicable
47 Immunologic Factors Phase 3,Not Applicable
48 Angiogenesis Modulating Agents Phase 3,Not Applicable
49
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
50 Analgesics Phase 1, Phase 2,Not Applicable

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients Completed NCT00972426 Phase 4 carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
2 COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy Completed NCT01228149 Phase 4 Trabeculectomy with preoperative Diamox/DexaEDO treatment;Trabeculectomy with preoperative Cosopt S treatment
3 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
4 Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis Completed NCT02641457 Phase 3 Aflibercept;Ranibizumab
5 Aqueous Mushroom Extract and Intraocular Pressure Unknown status NCT01017068 Phase 1, Phase 2 OME;OME;OME;OME;OME;OME
6 COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED) Completed NCT00832377 Phase 2 timolol/dorzolamide combination
7 A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Completed NCT01123785 Phase 1, Phase 2 INO-8875;Placebo
8 Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery Unknown status NCT02846090 Not Applicable Dexmedetomidine to reduce the IOP
9 Clinical Evaluation of CATS Tonometer Prism Completed NCT02990169 Not Applicable
10 Long-Term IOP Fluctuation and VF Progression After Triple Procedure Completed NCT00428740
11 PIO Laser Sclerectomy IOP SLT Sclerectomy Completed NCT01798732 Not Applicable
12 Melatonin Decreases Eye Pressure in Normotensive Patients Completed NCT03193112 Agomelatine 25 MG Oral Tablet
13 Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab Completed NCT00892398 Not Applicable ranibizumab
14 Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes Completed NCT00773136 Not Applicable Bimatoprost Suspension
15 Comparison of Phacotrabeculectomy and Trabeculectomy in the Treatment of Primary Angle-closure Glaucoma (PACG) Completed NCT01298635 Not Applicable
16 Selective Laser Trabeculoplasty After Failed Phacoemulsification With Eximer Laser Trabeculectomy Completed NCT02434250 Not Applicable
17 Primary Angle Closure Glaucoma and Aqueous Dynamics Completed NCT00719290 Not Applicable
18 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments Completed NCT01735214 Prostaglandin Analogue -Containing IOP-Lowering Therapy
19 Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension Completed NCT01489670 bimatoprost 0.01% ophthalmic solution
20 Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries Enrolling by invitation NCT03584958
21 Effect of Hyaluronidase on Intraocular Pressure Not yet recruiting NCT03266406 Not Applicable Hyaluronidase

Search NIH Clinical Center for Ocular Hypotension

Cochrane evidence based reviews: ocular hypotension

Genetic Tests for Ocular Hypotension

Anatomical Context for Ocular Hypotension

MalaCards organs/tissues related to Ocular Hypotension:

41
Eye, Brain, Heart

Publications for Ocular Hypotension

Articles related to Ocular Hypotension:

(show all 45)
# Title Authors Year
1
Treatment of chronic and extreme ocular hypotension following glaucoma surgery with intraocular platelet-rich plasma: A case report. ( 30295074 )
2018
2
RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis. ( 30456419 )
2018
3
Morphine-induced ocular hypotension is modulated by nitric oxide and carbon monoxide: role of mu3 receptors. ( 20148660 )
2010
4
Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy. ( 21434594 )
2010
5
Prolonged ocular hypotension: would ciliary tissue transplantation help. ( 19098698 )
2009
6
Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. ( 19234340 )
2009
7
Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. ( 17238805 )
2006
8
Fadolmidine-induced ocular hypotension in normotensive rabbits. ( 15720782 )
2005
9
PD128,907 induces ocular hypotension in rabbits: involvement of D2/D3 dopamine receptors and brain natriuretic peptide. ( 15006155 )
2004
10
Ocular hypotension induced by electroacupuncture. ( 12222760 )
2002
11
8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. ( 10433858 )
1999
12
Mechanism of exercise-induced ocular hypotension. ( 10102302 )
1999
13
Ocular hypotension induced by intravitreally injected C-type natriuretic peptide. ( 9533834 )
1998
14
Lisuride acts at multiple sites to induce ocular hypotension and mydriasis. ( 9742290 )
1998
15
Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. ( 9851310 )
1998
16
Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine. ( 9436152 )
1997
17
Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. ( 8921215 )
1996
18
Centrally mediated ocular hypotension: potential role of imidazoline receptors. ( 7677360 )
1995
19
Evaluation of IBMX-enhanced ocular hypotension after adrenergic agonists in the rabbit eye. ( 7542619 )
1995
20
Correlates of acute exercise-induced ocular hypotension. ( 7928182 )
1994
21
Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. ( 7925603 )
1994
22
Ocular hypotension during short- and long-term hypocapnia. ( 19920601 )
1994
23
Long-term visual outcome of ocular hypotension after thermosclerostomy. ( 8488912 )
1993
24
PhXA34-induced ocular hypotension. ( 1463535 )
1992
25
Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. ( 1349879 )
1992
26
Reattachment of the detached ciliary body with suturing for treatment of contusional ocular hypotension. ( 1896179 )
1991
27
Isobutylmethylxanthine enhances adrenergic-induced ocular hypotension in rabbits and beagles. ( 1712310 )
1991
28
Soluble forms of isobutylmethylxanthine enhance the ocular hypotension induced by catecholamines. ( 1722476 )
1991
29
Sustained decreases in systemic blood pressure do not cause ocular hypotension. ( 2710496 )
1989
30
Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. ( 2737263 )
1989
31
Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. ( 3477218 )
1987
32
Ocular hypotension in the rabbit. Receptor mechanisms of pirbuterol and nylidrin. ( 2857689 )
1985
33
Effect of pilocarpine in ocular hypotension. ( 3982788 )
1985
34
Forskolin suppresses sympathetic neuron function and causes ocular hypotension. ( 4039243 )
1985
35
Inflow and outflow relations after intraocular fluid-Healon exchange in a case of chronic ocular hypotension. ( 4086174 )
1985
36
Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. ( 6098513 )
1984
37
Comparative study of aqueous and oily pilocarpine in the production of ocular hypotension. ( 7295614 )
1981
38
Mature secondary cataracts and reversible ocular hypotension. ( 6992009 )
1980
39
Effect of vehicle on pilocarpine-induced ocular hypotension. ( 735763 )
1978
40
Possibility of isoproterenol therapy with soft contact lenses: ocular hypotension without systemic effects. ( 962259 )
1976
41
Ocular hypotension and massage of the eyeball. ( 4718630 )
1973
42
The recovery phase after ocular hypotension induced by compression. ( 5542865 )
1971
43
Dose response analysis of pilocarpine-induced ocular hypotension. ( 5478886 )
1970
44
Ocular hypotension in a population survey. ( 5359506 )
1969
45
Ocular hypotension with glycerol in cataract surgery. ( 5222692 )
1966

Variations for Ocular Hypotension

Expression for Ocular Hypotension

Search GEO for disease gene expression data for Ocular Hypotension.

Pathways for Ocular Hypotension

Pathways related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 ADRB1 ADRB2 HTR2B PDE4A PDE4B PDE4D
2
Show member pathways
12.47 ADRB1 ADRB2 PDE4A PDE4B PDE4D
3
Show member pathways
12.3 PDE4A PDE4B PDE4D
4 12.25 ADRB1 ADRB2 PDE4B
5
Show member pathways
12.21 PDE4A PDE4B PDE4D
6
Show member pathways
12.12 ADRB2 PDE4A PDE4B PDE4D
7
Show member pathways
12.05 ADRB1 ADRB2 PDE4A
8
Show member pathways
12.05 ADRB1 ADRB2 PDE4B PDE4D
9
Show member pathways
11.93 ADRB1 ADRB2 HTR2B
10 11.74 ADRB1 ADRB2 PDE4B
11
Show member pathways
11.67 ADRB1 ADRB2 HTR2B
12
Show member pathways
11.66 ADRB1 ADRB2 PDE4A PDE4B PDE4D
13 11.61 PDE4A PDE4B PDE4D
14 11.54 ADRB1 HTR2B
15 11.54 PDE4A PDE4D
16
Show member pathways
11.5 PDE4A PDE4B PDE4D
17 11.4 ADRB1 ADRB2
18 11.32 ADRB1 ADRB2
19 11.3 ADRB1 ADRB2
20 11.19 ADRB1 ADRB2 PDE4A PDE4B PDE4D
21 10.86 ADRB1 ADRB2

GO Terms for Ocular Hypotension

Cellular components related to Ocular Hypotension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated calcium channel complex GO:0005891 8.62 PDE4B PDE4D

Biological processes related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.8 ADRB1 ADRB2 HTR2B PDE4A PDE4B PDE4D
2 T cell receptor signaling pathway GO:0050852 9.62 PDE4B PDE4D
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.61 ADRB1 ADRB2
4 positive regulation of cold-induced thermogenesis GO:0120162 9.61 ADRB1 ADRB2
5 neutrophil chemotaxis GO:0030593 9.6 PDE4B PDE4D
6 cellular response to drug GO:0035690 9.59 PDE4A PDE4B
7 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.58 ADRB1 ADRB2
8 positive regulation of interferon-gamma production GO:0032729 9.58 PDE4B PDE4D
9 response to cold GO:0009409 9.57 ADRB1 ADRB2
10 activation of adenylate cyclase activity GO:0007190 9.56 ADRB1 ADRB2
11 brown fat cell differentiation GO:0050873 9.55 ADRB1 ADRB2
12 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.54 ADRB1 ADRB2
13 smooth muscle contraction GO:0006939 9.52 HTR2B PDE4D
14 positive regulation of interleukin-2 production GO:0032743 9.51 PDE4B PDE4D
15 cellular response to epinephrine stimulus GO:0071872 9.49 PDE4B PDE4D
16 regulation of cardiac muscle cell contraction GO:0086004 9.48 PDE4B PDE4D
17 negative regulation of multicellular organism growth GO:0040015 9.46 ADRB1 ADRB2
18 adrenergic receptor signaling pathway GO:0071875 9.43 ADRB2 PDE4D
19 G protein-coupled receptor signaling pathway GO:0007186 9.43 ADRB1 ADRB2 HTR2B PDE4A PDE4B PDE4D
20 diet induced thermogenesis GO:0002024 9.4 ADRB1 ADRB2
21 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.37 ADRB1 ADRB2
22 heat generation GO:0031649 9.26 ADRB1 ADRB2
23 negative regulation of relaxation of cardiac muscle GO:1901898 9.16 PDE4B PDE4D
24 cAMP catabolic process GO:0006198 8.8 PDE4A PDE4B PDE4D

Molecular functions related to Ocular Hypotension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel binding GO:0044325 9.46 PDE4B PDE4D
2 drug binding GO:0008144 9.43 HTR2B PDE4D
3 3',5'-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.4 PDE4B PDE4D
4 adrenergic receptor activity GO:0004935 9.37 ADRB1 ADRB2
5 phosphoric diester hydrolase activity GO:0008081 9.33 PDE4A PDE4B PDE4D
6 epinephrine binding GO:0051379 9.32 ADRB1 ADRB2
7 norepinephrine binding GO:0051380 9.26 ADRB1 ADRB2
8 cAMP binding GO:0030552 9.13 PDE4A PDE4B PDE4D
9 3',5'-cyclic-AMP phosphodiesterase activity GO:0004115 8.8 PDE4A PDE4B PDE4D

Sources for Ocular Hypotension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....